Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD-1 inhibitor + gemcitabine + vinorelbine + doxorubicin liposome
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination chemo-immunotherapy regimen is being investigated by Sun Yat-sen University Cancer Center for the treatment of relapsed or refractory classical Hodgkin lymphoma (cHL). The regimen integrates a programmed cell death protein 1 (PD-1) inhibitor with the GVD chemotherapy backbone, which consists of gemcitabine, vinorelbine, and liposomal doxorubicin. The PD-1 inhibitor acts as a checkpoint inhibitor to restore T-cell mediated anti-tumor activity by blocking the interaction between PD-1 and its ligands. The chemotherapy components provide complementary cytotoxic effects: gemcitabine inhibits DNA synthesis, vinorelbine disrupts microtubule assembly, and liposomal doxorubicin intercalates into DNA and inhibits topoisomerase II. Clinical research has demonstrated that this combination significantly improves complete remission rates and event-free survival in patients who have failed first-line induction therapy compared to standard GVD chemotherapy alone.
- Other names
- PD-1 inhibitor plus GVD regimenPD1 inhibitor plus GVD regimenPD 1 inhibitor plus GVD regimenPD-1 inhibitor + gemcitabine + vinorelbine + liposomal doxorubicin
02
Targets
TOP2A (DNA topoisomerase II)DNATUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on PD-1 inhibitor + gemcitabine + vinorelbine + doxorubicin liposome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD-1 inhibitor + gemcitabine + vinorelbine + doxorubicin liposome.